​

Exagen (XGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XGN Stock Forecast

Exagen (XGN) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $11.00 and a low of $8.00. This represents a 20.32% increase from the last price of $7.48.

$2 $4 $6 $8 $10 $12 High: $11 Avg: $9 Low: $8 Last Closed Price: $7.48

XGN Stock Rating

Exagen stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

XGN Price Target Upside V Benchmarks

TypeNameUpside
StockExagen20.32%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks1.69%

Price Target Trends

1M3M12M
# Anlaysts118
Avg Price Target$11.00$11.00$9.88
Last Closing Price$7.48$7.48$7.48
Upside/Downside47.06%47.06%32.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-7---7
Sep, 26-7---7
Aug, 26-7---7
Jul, 26-8---8
Jun, 26-7---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 19, 2026Kyle MiksonCanaccord Genuity$11.00$7.7242.49%47.06%
Jun 24, 2026Roth Capital$8.00$4.5276.99%6.95%
May 12, 2026BTIG$8.00$3.98101.01%6.95%
Apr 20, 2026Canaccord Genuity$8.00$2.97169.36%6.95%
Mar 11, 2026UBS$10.00$3.11221.54%33.69%
Mar 10, 2026Mark MassaroBTIG$9.00$3.25176.92%20.32%
Feb 17, 2026Mark MassaroBTIG$10.00$3.28204.88%33.69%
Oct 27, 2025Canaccord Genuity$15.00$11.9625.42%100.53%
Oct 14, 2025KeyBanc$15.00$11.0435.87%100.53%
Jul 30, 2025Cantor Fitzgerald$10.00$8.6315.87%33.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.BuyBuyhold
Aug 05, 2026Cowen & Co.BuyBuyhold
Aug 05, 2026B. RileyBuyBuyhold
Jun 24, 2026Roth CapitalBuyinitialise
Mar 10, 2026BTIGBuyBuyhold
Mar 10, 2026William BlairOutperformOutperformhold
Feb 17, 2026BTIGBuyBuyhold
Nov 05, 2025B. RileyBuyBuyhold
Oct 14, 2025KeyBancOverweightOverweighthold
Sep 11, 2025B. RileyBuyinitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.68$-2.77$-1.34$-0.83$-0.93---
Avg Forecast$-1.75$-2.71$-1.47$-0.89$-0.68$-0.45$-0.36$-0.14
High Forecast$-1.73$-2.63$-1.41$-0.87$-0.53$-0.33$-0.35$-0.13
Low Forecast$-1.81$-2.86$-1.64$-0.90$-0.82$-0.59$-0.40$-0.16
Surprise %-4.00%2.21%-8.84%-6.74%36.76%---

Revenue Forecast

$40M $53M $66M $79M $92M $105M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$48.30M$45.56M$52.55M$55.64M$66.58M---
Avg Forecast$47.30M$41.59M$50.32M$55.73M$66.40M$74.28M$82.90M$93.60M
High Forecast$48.39M$43.37M$50.59M$60.82M$67.38M$76.05M$87.30M$102.15M
Low Forecast$46.75M$40.72M$50.09M$54.09M$65.42M$72.50M$78.50M$90.85M
Surprise %2.12%9.55%4.44%-0.17%0.26%---

Net Income Forecast

$-55M $-44M $-33M $-22M $-11M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-26.85M$-47.39M$-23.69M$-15.12M$-19.95M---
Avg Forecast$-31.01M$-47.83M$-27.01M$-15.67M$-11.92M$-8.50M$-6.80M$-2.48M
High Forecast$-30.54M$-46.53M$-24.97M$-15.41M$-9.33M$-5.79M$-6.12M$-2.38M
Low Forecast$-31.94M$-50.50M$-29.04M$-15.94M$-14.51M$-10.35M$-7.12M$-2.77M
Surprise %-13.41%-0.93%-12.29%-3.57%67.36%---

XGN Forecast FAQ

Is Exagen stock a buy?

Exagen stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Exagen is a favorable investment for most analysts.

What is Exagen's price target?

Exagen's price target, set by 10 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $8 at the low end to $11 at the high end, suggesting a potential 20.32% change from the previous closing price of $7.48.

How does Exagen stock forecast compare to its benchmarks?

Exagen's stock forecast shows a 20.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (1.69%).

What is the breakdown of analyst ratings for Exagen over the past three months?

  • October 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Exagen’s EPS forecast?

Exagen's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.45, marking a -51.61% decrease from the reported $-0.93 in 2025. Estimates for the following years are $-0.36 in 2027, and $-0.14 in 2028.

What is Exagen’s revenue forecast?

Exagen's average annual revenue forecast for its fiscal year ending in December 2026 is $74.28M, reflecting a 11.57% increase from the reported $66.58M in 2025. The forecast for 2027 is $82.9M, and $93.6M for 2028.

What is Exagen’s net income forecast?

Exagen's net income forecast for the fiscal year ending in December 2026 stands at $-8.5M, representing a -57.40% decrease from the reported $-19.951M in 2025. Projections indicate $-6.8M in 2027, and $-2.475M in 2028.